• linkedin
  • Increase Font
  • Sharebar

    9 Newly Approved Novel Drugs

    It's been a busy year for the FDA.

     

    Parsabiv

    2. Parsabiv (etelcalcetide), Amgen

    Indication: A calcimimetic approved to manage secondary hyperparathyroidism in adults with chronic kidney disease who are on hemodialysis.

    Dosage: Recommended starting dose is 5 mg by IV bolus injection three times per week at the end of hemodialysis treatment.

    Contraindications: Known hypersensitivity to etelcalcetide or any of its excipients.

    Read the report here

    Read the full prescribing information here

    Previous ButtonNext Button

     

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available